Disease/Infection News

RSS

ProPhase Labs introduces new Cold-EEZE Oral Spray

ProPhase Labs, makers of Cold-EEZE, a leader in over-the-counter (OTC) homeopathic cold remedies, continues to pioneer the category as they launch their first-ever Cold-EEZE Oral Spray. The new Oral Spray is formulated with zinc gluconate, the same effective active ingredient found in the best-selling, clinically proven and #1 pharmacist recommended Cold-EEZE lozenges.

1 Nov 2011

Countries need vigilance, informed media coverage to achieve polio eradication

In this SciDev.Net editorial, T.V. Padma, regional coordinator for South Asia for the news service, recaps findings from the latest report of the Independent Monitoring Board of the Global Polio Eradication Initiative (GPEI), released last week, and writes, "Polio control in developing countries has received massive international support and funding, including free supplies of vaccines. Yet transmission of the virus remains. Clearly, there are problems other than funds."

1 Nov 2011

Pharmasset initiates PSI-7977 Phase 3 program for HCV

Pharmasset, Inc. today announced the initiation of a Phase 3 program with the hepatitis C virus (HCV) nucleotide analog, PSI-7977. This pivotal program will evaluate a 12-week, all-oral, interferon-free regimen of PSI-7977 and ribavirin in patients with HCV, independent of viral genotype or their ability to take interferon therapy.

1 Nov 2011

USAID has technical capacity to lead GHI if given authority

In a post in the Center for Global Development's "Rethinking U.S. Foreign Assistance Blog," Nandini Oomman, director of the HIV/AIDS Monitor at the center, and Rachel Silverman, a research assistant at the center, examine the question of Global Health Initiative (GHI) leadership, citing the State Department's Quadrennial Diplomacy and Development Review (QDDR), released last December, which states that "USAID would assume leadership of the GHI by September 2012, contingent upon fulfilling a set of 10 benchmarks to demonstrate its capacity."

1 Nov 2011

PlusNews interviews Stop TB Director Mario Raviglione

At the recent International Lung Health Conference in Lille, France, IRIN/PlusNews spoke with Stop TB Director Mario Raviglione about the threat of drug-resistant tuberculosis (TB), its treatment and "the precarious TB funding gap," the news service writes.

1 Nov 2011

Studies on effectiveness of new HCV therapies presented at 76th ACG meeting

Studies reporting on the effectiveness of new therapies for chronic Hepatitis C virus are among the clinical science presented at the American College of Gastroenterology's 76th Annual Scientific Meeting, where investigators also presented findings from an age-based risk assessment and screening intervention for Hepatitis C among Baby Boomers, patients aged 50-65, who saw a gastroenterologist for routine colon cancer screening.

1 Nov 2011

GPEI must 'take seriously' recommendations in Independent Monitoring Board report

In this post in the "Health Affairs Blog," diplomacy and global health consultant Judith Kaufmann writes about the Global Polio Eradication Initiative (GPEI) Independent Monitoring Board quarterly report released last week, stating, "What is really new about this report ... is that it does not, as so many GPEI reports have in the past, point the finger at lack of funding, although there is an obvious concern about the funding gap. Rather, the report looks squarely at changes needed in the management of the global program itself."

1 Nov 2011

Commonwealth government leaders pledge millions of additional funds to fight polio

"Commonwealth government leaders meeting in Australia agreed Saturday to step up efforts to eradicate polio worldwide, despite the Afghanistan war setting back vaccination efforts there and in neighboring Pakistan," the Associated Press reports.

1 Nov 2011

Vampire-like bacteria has potential to serve as living antibiotic

A vampire-like bacteria that leeches onto specific other bacteria - including certain human pathogens - has the potential to serve as a living antibiotic for a range of infectious diseases, a new study indicates.

1 Nov 2011

Light-cell interaction and Born approximation rule can help detect misshapen red blood cells

Misshapen red blood cells are a sign of serious illnesses, such as malaria and sickle cell anemia. Until recently, the only way to assess whether a person's RBCs were the correct shape was to look at them individually under a microscope - a time-consuming process for pathologists.

1 Nov 2011

Colonoscopic FMT effective in treating IBD, C.difficile-associated diarrhea

Growing evidence for the effectiveness of fecal microbiota transplants as a treatment for patients with recurrent bouts of Clostridium difficile (C.difficile) associated diarrhea is presented in three studies -- including a long-term follow-up of colonoscopic fecal microbiota transplant (FMT) for recurrent C. difficile Infection that included 77 patients from five different states-- unveiled today at the American College of Gastroenterology's (ACG) 76th Annual Scientific meeting in Washington, DC.

1 Nov 2011

Potential transmission of HBV, HCV and HIV infections in nail salons and barbershops

The risk of hepatitis transmission through non-single use instruments -- such as nail files, nail brushes, finger bowls, foot basins, buffers, razors, clippers, and scissors -- during nail salon and barbershop visits cannot be excluded, according to the results of a new report unveiled today at the American College of Gastroenterology's (ACG) 76th Annual Scientific meeting in Washington, DC.

1 Nov 2011

Panel backs anthrax vaccine testing on children

An important panel of government advisers Friday recommended that the government should sponsor a controversial study to test the anthrax vaccine in children to see whether the inoculation would protect young Americans against a bioterrorist's attack.

31 Oct 2011

PEPFAR and women's health in South Africa

This report, titled "Improving Women's Heath in South Africa: Opportunities for PEPFAR," by Janet Fleischman of the Center for Strategic and International Studies, says that with "major change ... unfolding in health and HIV services in South Africa," "[t]he United States can find feasible, flexible ways to support" the decentralization of "HIV services to the primary care level ... even though its health program through the President's Emergency Plan for AIDS Relief (PEPFAR) is scaling down.

31 Oct 2011

FDA grants Premarket Approval for Roche's IgM antibody to hepatitis B core antigen assay

Roche announced today that the U.S. Food and Drug Administration granted Premarket Approval for its IgM antibody to hepatitis B core antigen (Anti-HBc IgM) assay for use on the cobas e 601 analyzer, the immunoassay module of the cobas 6000 analyzer series for mid-volume laboratories.

From Roche Sequencing and Life Science 31 Oct 2011

Nursing home residence may allow for 'on-admission' prediction model of C. difficile infection severity

Antibiotics may not be the only risk factor associated with community-acquired Clostridium difficile infection, indicating that other undefined causes of the potentially life-threatening infection may exist and could also predict whether or not a patient will require hospitalization, according to the results of the study, "Predictors of Hospitalization in Community-Acquired Clostridium difficile Infection."

31 Oct 2011

Gen-Probe receives FDA approval for APTIMA HPV assay

Gen-Probe Incorporated announced today that the US Food and Drug Administration (FDA) has approved its APTIMA HPV assay, an amplified nucleic acid test that detects high-risk strains of human papillomavirus (HPV) that are associated with cervical cancer and precancerous lesions.

31 Oct 2011

New antibiotic regimes may increase infections after specific surgical procedures

The introduction of new antibiotic regimes to tackle hospital-acquired infections, such as C. difficile, must take into account the possibility of increased infections following specific surgical procedures.

31 Oct 2011

Astex to present data on direct acting antiviral agents against HCV at 62nd AASLD meeting

Astex Pharmaceuticals, Inc., a pharmaceutical company dedicated to the discovery, development and commercialization of novel therapeutics, announced that it will present data on its novel, first-in-class direct acting antiviral agents (DAA) against Hepatitis C Virus (HCV) at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco, November 4-8, 2011.

31 Oct 2011

Fierce Vaccines highlights Inovio's VGX-3100 as one of 10 Promising Therapeutic Vaccines

Inovio Pharmaceuticals, Inc., which is advancing synthetic vaccines to fight cancers and infectious diseases, announced today that VGX-3100, its investigational SynCon vaccine for treating cervical dysplasia and cancer caused by human papillomavirus, was highlighted by Fierce Vaccines as one of 10 Promising Therapeutic Vaccines.

31 Oct 2011

Disease/Infection News

ProPhase Labs introduces new Cold-EEZE Oral Spray

Countries need vigilance, informed media coverage to achieve polio eradication

Pharmasset initiates PSI-7977 Phase 3 program for HCV

USAID has technical capacity to lead GHI if given authority

PlusNews interviews Stop TB Director Mario Raviglione

Studies on effectiveness of new HCV therapies presented at 76th ACG meeting

GPEI must 'take seriously' recommendations in Independent Monitoring Board report

Commonwealth government leaders pledge millions of additional funds to fight polio

Vampire-like bacteria has potential to serve as living antibiotic

Light-cell interaction and Born approximation rule can help detect misshapen red blood cells

Colonoscopic FMT effective in treating IBD, C.difficile-associated diarrhea

Potential transmission of HBV, HCV and HIV infections in nail salons and barbershops

Panel backs anthrax vaccine testing on children

PEPFAR and women's health in South Africa

FDA grants Premarket Approval for Roche's IgM antibody to hepatitis B core antigen assay

Nursing home residence may allow for 'on-admission' prediction model of C. difficile infection severity

Gen-Probe receives FDA approval for APTIMA HPV assay

New antibiotic regimes may increase infections after specific surgical procedures

Astex to present data on direct acting antiviral agents against HCV at 62nd AASLD meeting

Fierce Vaccines highlights Inovio's VGX-3100 as one of 10 Promising Therapeutic Vaccines

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News